|
1
|
Dalal M, Hentrich M, Stamatoullas-Bastard A, Zagadailov E, Gautam A, Way N, Cambron-Mellott M, Illidge T. CLINICAL OUTCOMES ASSOCIATED WITH THE TREATMENT OF NEWLY DIAGNOSED STAGE IV CLASSICAL HODGKIN LYMPHOMA IN PRACTICE SETTINGS IN FRANCE, GERMANY AND THE UNITED KINGDOM. Hematol Oncol 2019. [DOI: 10.1002/hon.167_2631] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/10/2022]
Affiliation(s)
- M.R. Dalal
- Global Outcomes Research & Epidemiology (Oncology); Millennium Pharmaceuticals, Inc., a wholly owned subsidiary of Takeda Pharmaceutical Company Ltd, Cambridge, MA, USA; Cambridge United States
| | | | | | - E.A. Zagadailov
- Global Outcomes Research & Epidemiology (Oncology); Millennium Pharmaceuticals, Inc., a wholly owned subsidiary of Takeda Pharmaceutical Company Ltd, Cambridge, MA, USA; Cambridge United States
| | - A. Gautam
- Global Outcomes Research & Epidemiology (Oncology); Millennium Pharmaceuticals, Inc., a wholly owned subsidiary of Takeda Pharmaceutical Company Ltd, Cambridge, MA, USA; Cambridge United States
| | - N.A. Way
- Health Outcomes Practice; Kantar Health; San Mateo United States
| | | | - T.M. Illidge
- University of Manchester; Christie Hospital; Manchester United Kingdom
| |
Collapse
|
|
2
|
Prince H, Dummer R, Whittaker S, Horwitz S, Duvic M, Scarisbrick J, Quaglino P, Zinzani P, Wolter P, Sanches J, Ortiz-Romero P, Akilov O, Geskin L, Huen A, Wang Y, Palanca-Wessels M, Richhariya A, Feliciano J, Zhu Y, Lin H, Liu Y, Little M, Zagadailov E, Dalal M, Kim Y. PATIENT-REPORTED OUTCOMES AND QUALITY OF LIFE IN PATIENTS WITH CUTANEOUS T CELL LYMPHOMA: RESULTS FROM THE PHASE 3 ALCANZA STUDY. Hematol Oncol 2017. [DOI: 10.1002/hon.2438_110] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/06/2022]
Affiliation(s)
- H.M. Prince
- Division of Cancer Medicine, Peter MacCallum Cancer Centre and Sir Peter MacCallum Department of Oncology; The University of Melbourne; Melbourne Australia
| | - R. Dummer
- Department of Dermatology; University Hospital Zürich; Zürich Switzerland
| | - S. Whittaker
- St John's Institute of Dermatology; Guys and St Thomas NHS Foundation Trust; London UK
| | - S. Horwitz
- Department of Medicine; Memorial Sloan Kettering Cancer Center; New York USA
| | - M. Duvic
- Department of Dermatology; The University of Texas MD Anderson Cancer Center; Houston USA
| | - J. Scarisbrick
- Department of Dermatology; University Hospital Birmingham; Birmingham UK
| | - P. Quaglino
- Department of Medical Sciences, Dermatologic Clinic; University of Turin; Turin Italy
| | - P.L. Zinzani
- Institute of Haematology; University of Bologna; Bologna Italy
| | - P. Wolter
- Department of General Medical Oncology; University Hospitals Leuven; Leuven Belgium
| | - J. Sanches
- Department of Dermatology; University of São Paulo Medical School; São Paulo Brazil
| | - P. Ortiz-Romero
- Department of Dermatology; University Hospital 12 de Octubre, Institute i+12 Medical School, University Complutense; Madrid Spain
| | - O. Akilov
- Department of Dermatology; University of Pittsburgh; Pittsburgh USA
| | - L. Geskin
- Department of Dermatology; University of Pittsburgh; Pittsburgh USA
| | - A. Huen
- Department of Dermatology; The University of Texas MD Anderson Cancer Center; Houston USA
| | - Y. Wang
- Biometrics; Seattle Genetics, Inc.; Bothell USA
| | | | - A. Richhariya
- Market Access & Health Economics; Seattle Genetics, Inc.; Bothell USA
| | - J. Feliciano
- Value and Access; Seattle Genetics, Inc.; Bothell USA
| | - Y. Zhu
- Global Statistics; Millennium Pharmaceuticals Inc., a wholly owned subsidiary of Takeda Pharmaceutical Company Limited; Cambridge USA
| | - H. Lin
- Biostatistics; Millennium Pharmaceuticals Inc., a wholly owned subsidiary of Takeda Pharmaceutical Company Limited; Cambridge USA
| | - Y. Liu
- Biostatistics; Millennium Pharmaceuticals Inc., a wholly owned subsidiary of Takeda Pharmaceutical Company Limited; Cambridge USA
| | - M. Little
- Oncology Clinical Research; Millennium Pharmaceuticals Inc., a wholly owned subsidiary of Takeda Pharmaceutical Company Limited; Cambridge USA
| | - E. Zagadailov
- Global Outcomes Research; Millennium Pharmaceuticals Inc., a wholly owned subsidiary of Takeda Pharmaceutical Company Limited; Cambridge USA
| | - M. Dalal
- Global Outcomes Research; Millennium Pharmaceuticals Inc., a wholly owned subsidiary of Takeda Pharmaceutical Company Limited; Cambridge USA
| | - Y.H. Kim
- Department of Dermatology; Stanford University School of Medicine and Stanford Cancer Institute; Stanford USA
| |
Collapse
|
|
3
|
Dalal M, Mitchell S, McCloskey C, Zagadailov E, Gautam A. Long-term quality of life in patients with advanced Hodgkin lymphoma: A systematic review. Hematol Oncol 2017. [DOI: 10.1002/hon.2439_50] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/07/2022]
Affiliation(s)
- M.R. Dalal
- Global Outcomes Research; Takeda Pharmaceuticals International Co.; Cambridge MA USA
| | | | | | - E.A. Zagadailov
- Global Outcomes Research; Takeda Pharmaceuticals International Co.; Cambridge MA USA
| | - A. Gautam
- Global Medical Affairs; Takeda Pharmaceuticals International Co.; Cambridge UK
| |
Collapse
|
|
4
|
Dalal M, Mitchell S, McCloskey C, Zagadailov E, Gautam A. EPIDEMIOLOGICAL AND HUMANISTIC BURDEN OF CUTANEOUS T-CELL LYMPHOMAS: RESULTS OF a SYSTEMATIC REVIEW. Hematol Oncol 2017. [DOI: 10.1002/hon.2439_154] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/11/2022]
Affiliation(s)
- M.R. Dalal
- Global Outcomes Research, Takeda Pharmaceuticals International Co.; Cambridge USA
| | | | | | - E.A. Zagadailov
- Global Outcomes Research, Takeda Pharmaceuticals International Co.; Cambridge USA
| | - A. Gautam
- Takeda Pharmaceuticals International Co.; Global Medical Affairs; Cambridge USA
| |
Collapse
|
|
5
|
Kim Y, Whittaker S, Horwitz S, Duvic M, Dummer R, Scarisbrick J, Quaglino P, Zinzani P, Wolter P, Wang Y, Palanca-Wessels M, Zagadailov E, Trepicchio W, Lin H, Little M, Prince H. 262 Brentuximab vedotin demonstrates superior activity to standard therapy in CD30-expressing (CD30+) cutaneous T-cell lymphoma (CTCL) in the randomized phase 3 ALCANZA study. J Invest Dermatol 2017. [DOI: 10.1016/j.jid.2017.02.278] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/19/2022]
|